Browse Studies — Arctuva | Arctuva

Browse Studies About FAQ

Sign in Get started

Browse studies

Find your next paid study

1 recruiting study matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Low Risk Myelodysplastic Syndromes

Rigel PharmaceuticalsNCT05308264

Arctuva

Connecting verified participants with clinical studies that matter.

Platform

Browse Studies
Join Arctuva
My Profile

Company

About
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Arctuva. All rights reserved.